PTC Therapeutics, Inc.
PTCT
$46.39
$0.380.83%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 451.71% | 8.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 451.71% | 8.33% | |||
| Cost of Revenue | -13.62% | -18.12% | |||
| Gross Profit | 1,361.84% | 194.05% | |||
| SG&A Expenses | -4.40% | 15.28% | |||
| Depreciation & Amortization | 14.85% | 8.93% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.80% | -7.92% | |||
| Operating Income | 6,208.64% | 69.46% | |||
| Income Before Tax | 1,081.88% | 3.36% | |||
| Income Tax Expenses | 319.57% | -432.60% | |||
| Earnings from Continuing Operations | 1,415.24% | 38.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,415.24% | 38.22% | |||
| EBIT | 6,208.64% | 69.46% | |||
| EBITDA | 10,824.97% | 79.98% | |||
| EPS Basic | 1,399.89% | 38.45% | |||
| Normalized Basic EPS | 1,981.70% | 143.69% | |||
| EPS Diluted | 1,276.47% | 38.45% | |||
| Normalized Diluted EPS | 1,782.40% | 143.69% | |||
| Average Basic Shares Outstanding | 1.18% | 0.36% | |||
| Average Diluted Shares Outstanding | 11.90% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||